霍奇金淋巴瘤组织中H／RS细胞与其背景细胞的微切割及其IgH基因重排检测

目的 从基因水平探讨霍奇金淋巴瘤(HL)组织中H／RS细胞(Hodgkin and Reed-Sternberg cells)是否起源于B细胞、H／RS细胞的克隆性以及与背景淋巴细胞的相互关系。方法 对33例经典霍奇金淋巴瘤(cHL)石蜡刮片组织进行IgH基因重排分析，并对其中6例重排阳性的病例经B细胞特异性激活蛋白(BSAP)免疫标记，将标记阳性的H／RS细胞和背景淋巴细胞进行微切割后进一步行IgH基因重排分析。结果 16例石蜡刮片组织IgH基因重排阳性。对6例经BSAP标记的cHL成功进行了微切割，其中19管H／RS细胞中，有14管出现重排阳性，细胞数目不同的各管阳性率无显著性差异(P=0．290)；12管背景淋巴细胞有2管出现重排阳性，H／RS细胞与背景淋巴细胞的阳性率有显著性差异(P=0．002)。结论 支持H／RS细胞来源于B细胞的理论，认为部分背景淋巴细胞可能具有瘤性增生活性，参与H／RS细胞的前体细胞组成。     

Pulmonary resection for metastases from colorectal cancer

Aim: The prognosis of patients with disseminated colorectal carcinoma is poor except for those with single organ pulmonary or hepatic metastases. The objective of the present study was to evaluate the result of pulmonary metastasectomy for colorectal secondary and to identify the prognostic factors. Methods: This was a retrospective study of 80 patients who had pulmonary metastasectomy for pulmonary secondary from colorectal carcinoma in Queen Elizabeth Hospital, Hong Kong. Results: The overall 5‐year and 10‐year survival rates of the entire cohort were 42.5% and 35.5%, respectively. High premetastasectomy carcinoembryonic antigen (> 20 μg/dL), short disease‐free interval (< 12 months) and incomplete resection were the independent prognostic factors. Neither the characteristics of the primary colorectal tumour nor the number of metastatic nodules had a significant contribution to the long‐term survival. Six patients underwent second pulmonary metastasectomy and three were still free from tumour recurrence after the second operation. Conclusion: Patients with pulmonary metastases from colorectal carcinoma would benefit from pulmonary metastasectomy. High premetastasectomy carcinoembryonic antigen and short disease‐free interval were negative predictive factors for survival. Long‐term follow‐up study is required, as recurrence can occur more than 5 years after pulmonary metastasectomy. Also, whether the survival benefit is due to surgical treatment effect or lead‐time bias remains undecided.     

MUC-1基因在胃癌和外周血中的表达及临床意义

目的：检测胃癌MUC－1的表达情况及其与临床分期和转移的相关性。方法：应用逆转录聚合酶链反应（RT－PCR）和免疫组化方法检测胃癌活检标本和外周血中MUC－1基因和蛋白的表达水平。结果：在56例胃癌病例中MUC－1 mRNA阳性表达率为48．2％，MUC－1蛋白阳性表达率为53．6％，临床分期中I和II期病人阳性表达率MUC－1 RNA为33．3％，MUC－1蛋白为40％，而-Ⅲ期病人则分别高达65．4％和69．2％，二者差异有显著性意义（P＜0．05），在淋巴结转移的患者中外周血的癌细胞MUC－1高表达，阳性率为73％，结论：MUC－1是一种较好反映胃癌恶性程度和转移性的肿瘤标志物。     

不同麻醉方式对上腹部手术患者血浆前列腺素和血栓素的影响

目的　观察不同的麻醉方法对上腹部手术患者血浆 6 酮 前列腺素F1α( 6 keto PGF1α ,PGF1α)和血栓素B2 (TXB2 )的影响。方法　择期上腹部手术患者 2 0例 ,随机分两组 :Ⅰ组为硬膜外麻醉组 ;Ⅱ组为全身麻醉组。于麻醉前、诱导后、手术 10min、手术 5 0min及术毕采静脉血 ,用放射免疫法测定血浆中PGF1α和TXB2 的含量。结果　 ( 1)PGF1α在Ⅰ组麻醉后升高 ,术毕明显高于术前 (P <0 .0 5 ) ;Ⅱ组诱导后下降 ,然后渐升 ,术毕达高峰 (P <0 .0 5 )。 ( 2 )TXB2 在Ⅰ组麻醉后均明显降低 (均为P <0 .0 1) ;Ⅱ组诱导后显著降低 (P <0 .0 1) ,但术毕却明显升高 (P <0 .0 5 )。 ( 3)PGF1α与TXB2 的比值 (K/T值 )在Ⅰ组麻醉后均显著升高 (均为P <0 .0 1) ,而Ⅱ组仅见诱导后显著增高。结论　硬膜外麻醉对减轻术后早期应激反应优于全麻     

改良W形回肠代膀胱术的疗效观察(附36例报告)

目的 :探讨改良W形回肠代膀胱术的疗效。方法 :对 36例膀胱肿瘤患者行根治性膀胱切除、W形回肠代膀胱术 ,并对术式进行改进。结果 :36例手术时间平均 4 .2h。术后 31例随访 4～ 19个月 ,平均 10 .6个月 ,无严重并发症 ,均无瘤生存。患者一般于术后 3周自主可控性排尿 ,日间尿控率为 10 0 % ,术后 3、6、12个月夜间尿失禁发生率分别为 2 2 .5 %、11.1%及 6 .2 %。术后 6个月尿动力学检查膀胱容量 (36 0± 30 )ml,最大尿流率 (13.6± 2 .6 )ml/s,剩余尿量 (11.5± 5 .8)ml,充盈期膀胱压力明显低于尿道闭合压。新膀胱造影发现新膀胱呈球形 ,完全位于盆腔 ,未见输尿管反流。B超及IVU检查发现原上尿路积水 4例均明显减轻 ,其余未发现输尿管狭窄和上尿路积水征象。无高氯性酸中毒 ,肾功能正常。结论 :改良W形回肠代膀胱术手术时间短 ,操作简单 ,创伤轻 ,并发症少 ;新膀胱容量大 ,内压低 ,顺应性好 ,功能接近于正常膀胱 ,保持原位排尿 ,明显提高了患者术后生活质量 ,值得临床推广应用。     

改良电针痉挛连续两次发作治疗重性抑郁症疗效分析

目的　探讨改良电针痉挛连续两次发作治疗重性抑郁症的疗效。方法　使用YA型电针痉挛治疗仪 ,对 64例重性抑郁症患者进行连续两次发作 (试验组 )和单次发作 (对照组 )治疗 ,采用HAMD抑郁量表评分。结果　试验组临床显效率为 82 3 % ,对照组为 60 0 % ,试验组的疗效显著性地优于对照组 (χ2 =3 94,P <0 0 5 )。HAMD抑郁量表评定 :两组治疗前后总分均值比较均有显著差异 (P <0 0 1) ,试验组和对照组治疗后总分均值有显著差异 (t=5 .10 8,P <0 0 1) ;两组 4次发作治疗后总分均值比较试验组显效快于对照组 ;试验组的绝望感、认知障碍、迟滞因子分均值减低比对照组更明显 (P <0 0 1)。结论　改良电针痉挛连续两次发作疗法见效快、疗效好 ,无明显副作用 ,是治疗重性抑郁症的一种新方法     

心理干预对错[牙合]畸形治疗中合作行为及结果的影响

目的：观察心理干预对错[牙合]畸形患者正畸治疗中合作行为及结果的影响。方法：对门诊口腔科60例青少年[牙合]畸形患者随机分为干预组和对照组各30例。两组均由从事正畸工作5年以上的主治医师采用标准方丝弓技术进行矫正治疗，干预组同时实施心理干预等心理治疗。将两组治疗中的合作行为和结果进行比较分析。结果：心理干预组自律性、主动性、自觉性、矫治时间、满意度等均明显优于对照组，差异有显著性（P〈0．01）。结论：心理干预对青少年正畸患者治疗中合作行为和结果有明显影响，通过心理干预能提高矫治的效果，保证治疗的顺利完成。     

脑卒中患者吞咽障碍及康复效果影像学研究

目的探讨电视X线透视吞咽功能检查（videofluoroscopic swallowing study,VFSS）在脑卒中患者吞咽功能评估中的应用价值,观察脑卒中后吞咽障碍发生情况,康复前后患者吞咽功能变化.方法脑卒中患者70例及健康成人80名分别作为研究组与对照组均进行VFSS,比较两组误吸等VFSS异常征象的发生情况.对发现误吸患者进行吞咽功能康复训练4周,训练后复查VFSS,比较训练前后吞咽异常的发生情况变化.结果对照组渗透或误吸、口腔滞留、咽腔滞留的发生率为5.0%,13.4%,25.3%.主要为轻度渗透及口咽腔滞留.研究组渗透或误吸、口腔滞留、咽腔滞留发生率为45.0%,46.5%,48.9%,主要为重度渗透或误吸,中重度口咽腔滞留.其中隐匿性误吸为10次（占总误吸的24.4%）.误吸患者康复治疗后渗透或误吸发生率较康复治疗前减少（P＜0.05）.结论脑卒中后吞咽障碍在康复期仍较为常见,可表现为多种影像学异常.VFSS可确切诊断吞咽异常,进行针对性康复训练,使患者吞咽功能提高.     

Recapitulation of fast skeletal muscle development in zebrafish by transgenic expression of GFP under the mylz2 promoter.

A 1,934-bp muscle-specific promoter from the zebrafish mylz2 gene was isolated and characterized by transgenic analysis. By using a series of 5' promoter deletions linked to the green fluorescent protein (gfp) reporter gene, transient transgenic analysis indicated that the strength of promoter activity appeared to correlate to the number of muscle cis-elements in the promoter and that a minimal -77-bp region was sufficient for a relatively strong promoter activity in muscle cells. Stable transgenic lines were obtained from several mylz2-gfp constructs. GFP expression in the 1,934-bp promoter transgenic lines mimicked well the expression pattern of endogenous mylz2 mRNA in both somitic muscle and nonsomitic muscles, including fin, eye, jaw, and gill muscles. An identical pattern of GFP expression, although at a much lower level, was observed from a transgenic line with a shorter 871-bp promoter. Our observation indicates that there is no distinct cis-element for activation of mylz2 in different skeletal muscles. Furthermore, RNA encoding a dominant negative form of cAMP-dependent protein kinase A was injected into mylz2-gfp transgenic embryos and GFP expression was significantly reduced due to an expanded slow muscle development at the expense of GFP-expressing fast muscle. The mylz2-gfp transgene was also transferred into two zebrafish mutants, spadetail and chordino, and several novel phenotypes in muscle development in these mutants were discovered.     

维拉帕米灌注治疗前列腺术后膀胱痉挛性疼痛的临床疗效观察

为探讨前列腺术后膀胱痉挛性疼痛的药物治疗效果，将２６例前列腺增生行耻骨上经膀胱前列腺摘除术后频繁发作膀胱逼尿肌无抑制性收缩导致膀胱痉挛性疼痛者，按随机抽样法分为两组，第１组１５例接受维拉帕米膀胱灌注治疗，第２组１１例作为对照，不用任何可能影响下尿中功能的药物。